<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00906373</url>
  </required_header>
  <id_info>
    <org_study_id>13931</org_study_id>
    <secondary_id>CP13-0812</secondary_id>
    <secondary_id>I5A-IE-JAEG</secondary_id>
    <nct_id>NCT00906373</nct_id>
  </id_info>
  <brief_title>A Study of IMC-A12 in Combination With Sorafenib in Patients With Advanced Cancer of the Liver</brief_title>
  <official_title>A Multicenter, Phase 2 Study Evaluating IMC-A12 in Combination With Sorafenib as First-Line Therapy for Patients With Advanced Hepatocellular Carcinoma (HCC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine if IMC-A12 given in combination with Sorafenib is safe and effective for
      patients with advanced liver cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to determine progression free survival (PFS) in patients with
      unresectable hepatocellular carcinoma who have received no prior systemic therapy when
      treated with IMC-A12 administered every three weeks in combination with oral sorafenib
      administered twice daily.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2009</start_date>
  <completion_date type="Actual">May 2014</completion_date>
  <primary_completion_date type="Actual">October 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>Approximately 2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Adverse Events (AEs)</measure>
    <time_frame>Approximately 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum concentration (Cmax) cycle 1</measure>
    <time_frame>Day 1</time_frame>
    <description>Within 14 days prior to the first infusion, immediately after the 1-hour infusion, 2-hours after the start of the infusion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum concentration (Cmax) cycle 1</measure>
    <time_frame>Day 8</time_frame>
    <description>168 hours after the start of the infusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum concentration (Cmax) cycle 1</measure>
    <time_frame>Day 15</time_frame>
    <description>336 hours after the start of the infusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum concentration (Cmax) Cycle 1</measure>
    <time_frame>Day 22</time_frame>
    <description>504 hours after the start of the infusion, immediately prior to the Cycle 2 infusion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimum concentration (Cmin) cycle 1</measure>
    <time_frame>Day 1</time_frame>
    <description>Within 14 days prior to the first infusion, immediately after the 1-hour infusion, 2-hours after the start of the infusion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimum concentration (Cmin) cycle 1</measure>
    <time_frame>Day 8</time_frame>
    <description>168 hours after the start of the infusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimum concentration (Cmin) cycle 1</measure>
    <time_frame>Day 15</time_frame>
    <description>336 hours after the start of the infusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimum concentration (Cmin) Cycle 1</measure>
    <time_frame>Day 22</time_frame>
    <description>504 hours after the start of the infusion, immediately prior to the Cycle 2 infusion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Half-Life (t 1/2) cycle 1</measure>
    <time_frame>Day 1</time_frame>
    <description>Within 14 days prior to the first infusion, immediately after the 1-hour infusion, 2-hours after the start of the infusion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Half-Life (t 1/2) cycle 1</measure>
    <time_frame>Day 8</time_frame>
    <description>168 hours after the start of the infusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Half-Life (t 1/2) cycle 1</measure>
    <time_frame>Day 15</time_frame>
    <description>336 hours after the start of the infusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Half-Life (t 1/2) cycle 1</measure>
    <time_frame>Day 22</time_frame>
    <description>504 hours after the start of the infusion, immediately prior to the Cycle 2 infusion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clearance (CL) cycle 1</measure>
    <time_frame>Day 1</time_frame>
    <description>Within 14 days prior to the first infusion, immediately after the 1-hour infusion, 2-hours after the start of the infusion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clearance (CL) cycle 1</measure>
    <time_frame>Day 8</time_frame>
    <description>168 hours after the start of the infusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clearance (CL) cycle 1</measure>
    <time_frame>Day 15</time_frame>
    <description>336 hours after the start of the infusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clearance (CL) cycle 1</measure>
    <time_frame>Day 22</time_frame>
    <description>504 hours after the start of the infusion, immediately prior to the Cycle 2 infusion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve (AUC) cycle 1</measure>
    <time_frame>Day 1</time_frame>
    <description>Within 14 days prior to the first infusion, immediately after the 1-hour infusion, 2-hours after the start of the infusion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve (AUC) cycle 1</measure>
    <time_frame>Day 8</time_frame>
    <description>168 hours after the start of the infusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve (AUC) cycle 1</measure>
    <time_frame>Day 15</time_frame>
    <description>336 hours after the start of the infusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve (AUC) cycle 1</measure>
    <time_frame>Day 22</time_frame>
    <description>504 hours after the start of the infusion, immediately prior to the Cycle 2 infusion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of Distribution at Steady State (Vd) cycle 1</measure>
    <time_frame>Day 1</time_frame>
    <description>Within 14 days prior to the first infusion, immediately after the 1-hour infusion, 2-hours after the start of the infusion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of Distribution at Steady State (Vd) cycle 1</measure>
    <time_frame>Day 8</time_frame>
    <description>168 hours after the start of the infusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of Distribution at Steady State (Vd) cycle 1</measure>
    <time_frame>Day 15</time_frame>
    <description>336 hours after the start of the infusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of Distribution at Steady State (Vd) cycle 1</measure>
    <time_frame>Day 22</time_frame>
    <description>504 hours after the start of the infusion, immediately prior to the Cycle 2 infusion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum concentration (Cmax) cycle 3</measure>
    <time_frame>Day 43</time_frame>
    <description>Immediately prior to the third infusion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum concentration (Cmax) cycle 3</measure>
    <time_frame>Day 44</time_frame>
    <description>24 hours after the start of the infusion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum concentration (Cmax) cycle 3</measure>
    <time_frame>Day 45</time_frame>
    <description>48 hours after the start of the infusion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum concentration (Cmax) cycle 3</measure>
    <time_frame>Day 46</time_frame>
    <description>72 hours after the start of the infusion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum concentration (Cmax) cycle 3</measure>
    <time_frame>Day 50</time_frame>
    <description>168 hours after the start of the infusion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum concentration (Cmax) cycle 3</measure>
    <time_frame>Day 53</time_frame>
    <description>240 hours after the start of the infusion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum concentration (Cmax) cycle 3</measure>
    <time_frame>Day 57</time_frame>
    <description>336 hours after the start of the infusion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum concentration (Cmax) cycle 3</measure>
    <time_frame>Day 64</time_frame>
    <description>504 hours after the start of the infusion, immediately prior to Cycle 4.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimum concentration (Cmin) cycle 3</measure>
    <time_frame>Day 43</time_frame>
    <description>Immediately prior to the third infusion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimum concentration (Cmin) cycle 3</measure>
    <time_frame>Day 44</time_frame>
    <description>24 hours after the start of the infusion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimum concentration (Cmin) cycle 3</measure>
    <time_frame>Day 45</time_frame>
    <description>48 hours after the start of the infusion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimum concentration (Cmin) cycle 3</measure>
    <time_frame>Day 46</time_frame>
    <description>72 hours after the start of the infusion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimum concentration (Cmin) cycle 3</measure>
    <time_frame>Day 50</time_frame>
    <description>168 hours after the start of the infusion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimum concentration (Cmin) cycle 3</measure>
    <time_frame>Day 53</time_frame>
    <description>240 hours after the start of the infusion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimum concentration (Cmin) cycle 3</measure>
    <time_frame>Day 57</time_frame>
    <description>336 hours after the start of the infusion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimum concentration (Cmin) cycle 3</measure>
    <time_frame>Day 64</time_frame>
    <description>504 hours after the start of the infusion, immediately prior to Cycle 4.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Half-Life (t 1/2) cycle 3</measure>
    <time_frame>Day 43</time_frame>
    <description>Immediately prior to the third infusion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Half-Life (t 1/2) cycle 3</measure>
    <time_frame>Day 44</time_frame>
    <description>24 hours after the start of the infusion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Half-Life (t 1/2) cycle 3</measure>
    <time_frame>Day 45</time_frame>
    <description>48 hours after the start of the infusion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Half-Life (t 1/2) cycle 3</measure>
    <time_frame>Day 46</time_frame>
    <description>72 hours after the start of the infusion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Half-Life (t 1/2) cycle 3</measure>
    <time_frame>Day 50</time_frame>
    <description>168 hours after the start of the infusion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Half-Life (t 1/2) cycle 3</measure>
    <time_frame>Day 53</time_frame>
    <description>240 hours after the start of the infusion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Half-Life (t 1/2) cycle 3</measure>
    <time_frame>Day 57</time_frame>
    <description>336 hours after the start of the infusion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Half-Life (t 1/2) cycle 3</measure>
    <time_frame>Day 64</time_frame>
    <description>504 hours after the start of the infusion, immediately prior to Cycle 4.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clearance (CL) cycle 3</measure>
    <time_frame>Day 43</time_frame>
    <description>Immediately prior to the third infusion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clearance (CL) cycle 3</measure>
    <time_frame>Day 44</time_frame>
    <description>24 hours after the start of the infusion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clearance (CL) cycle 3</measure>
    <time_frame>Day 45</time_frame>
    <description>48 hours after the start of the infusion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clearance (CL) cycle 3</measure>
    <time_frame>Day 46</time_frame>
    <description>72 hours after the start of the infusion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clearance (CL) cycle 3</measure>
    <time_frame>Day 50</time_frame>
    <description>168 hours after the start of the infusion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clearance (CL) cycle 3</measure>
    <time_frame>Day 53</time_frame>
    <description>240 hours after the start of the infusion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clearance (CL) cycle 3</measure>
    <time_frame>Day 57</time_frame>
    <description>336 hours after the start of the infusion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clearance (CL) cycle 3</measure>
    <time_frame>Day 64</time_frame>
    <description>504 hours after the start of the infusion, immediately prior to Cycle 4.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve (AUC) cycle 3</measure>
    <time_frame>Day 43</time_frame>
    <description>Immediately prior to the third infusion, 2 hours after the start of the infusion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve (AUC) cycle 3</measure>
    <time_frame>Day 44</time_frame>
    <description>24 hours after the start of the infusion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve (AUC) cycle 3</measure>
    <time_frame>Day 45</time_frame>
    <description>48 hours after the start of the infusion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve (AUC) cycle 3</measure>
    <time_frame>Day 46</time_frame>
    <description>72 hours after the start of the infusion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve (AUC) cycle 3</measure>
    <time_frame>Day 50</time_frame>
    <description>168 hours after the start of the infusion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve (AUC) cycle 3</measure>
    <time_frame>Day 53</time_frame>
    <description>240 hours after the start of the infusion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve (AUC) cycle 3</measure>
    <time_frame>Day 57</time_frame>
    <description>336 hours after the start of the infusion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve (AUC) cycle 3</measure>
    <time_frame>Day 64</time_frame>
    <description>504 hours after the start of the infusion, immediately prior to the Cycle 4 infusion..</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of distribution at steady state (Vd) cycle 3</measure>
    <time_frame>Day 43</time_frame>
    <description>Immediately prior to the third infusion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of distribution at steady state (Vd) cycle 3</measure>
    <time_frame>Day 44</time_frame>
    <description>24 hours after the start of the infusion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of distribution at steady state (Vd) cycle 3</measure>
    <time_frame>Day 45</time_frame>
    <description>48 hours after the start of the infusion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of distribution at steady state (Vd) cycle 3</measure>
    <time_frame>Day 46</time_frame>
    <description>72 hours after the start of the infusion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of distribution at steady state (Vd) cycle 3</measure>
    <time_frame>Day 50</time_frame>
    <description>168 hours after the start of the infusion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of distribution at steady state (Vd) cycle 3</measure>
    <time_frame>Day 53</time_frame>
    <description>240 hours after the start of the infusion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of distribution at steady state (Vd) cycle 3</measure>
    <time_frame>Day 57</time_frame>
    <description>336 hours after the start of the infusion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of distribution at steady state (Vd) cycle 3</measure>
    <time_frame>Day 64</time_frame>
    <description>504 hours after the start of the infusion, immediately prior to the Cycle 4 infusion..</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>Approximately 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Approximately 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to progression (TTP)</measure>
    <time_frame>Approximately 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response</measure>
    <time_frame>Approximately 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Anti-cixutumumab Antibody Assessment (immunogenicity)</measure>
    <time_frame>Approximately 2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">47</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Treatment cycles will repeat until there is evidence of progressive disease (PD), toxicity, or Withdrawal. If any participant experiences a dose-limiting toxicity (DLT), an additional 3 patients will be enrolled at this dose level (for a total of 6). If no further DLTs, enrollment into Cohort 2 will occur.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Treatment cycles will repeat until there is evidence of progressive disease (PD), toxicity, or Withdrawal.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>IMC-A12 (cixutumumab)</intervention_name>
    <description>intravenous infusions 10 mg/kg on day 1 of each 3 week cycle</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <other_name>cixutumumab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>IMC-A12 (cixutumumab)</intervention_name>
    <description>intravenous infusions 20 mg/kg on day 1 of each 3 week cycle</description>
    <arm_group_label>Cohort 2</arm_group_label>
    <other_name>cixutumumab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sorafenib</intervention_name>
    <description>400 mg twice per day orally</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The patient has histologically or cytologically confirmed, unresectable HCC

          -  The patient has at least one target lesion measurable according to Response Evaluation
             Criteria in Solid Tumors (RECIST) guidelines. Target lesion(s) must not lay within a
             previously irradiated, ablated, or chemoembolized area. If a lesion does lie in such
             an area, there must be evidence of growth on successive imaging studies, including
             tumor hypervascularity, in order for such a lesion to be considered a target lesion

          -  The patient has not received prior systemic therapy for HCC. Patients may have
             received prior embolization, chemoembolization, intra-arterial chemotherapy infusion,
             ethanol injection, radiofrequency ablation, or cryosurgery

          -  The patient has fasting serum glucose &lt; 160 mg/dL or below the ULN and/or hemoglobin
             A1C &lt; 7%. If baseline nonfasting glucose &lt; 160 mg/dL, fasting glucose measurement is
             not required

          -  The patient has the ability to understand and the willingness to sign a written
             informed consent document

        Exclusion Criteria:

          -  The patient has brain metastases

          -  The patient has acute hepatitis

          -  The patient has poorly controlled diabetes mellitus. Patients with a history of
             diabetes mellitus are allowed to participate, provided that their blood glucose is
             within normal range and that they are on a stable dietary or therapeutic regimen for
             this condition

          -  The patient has congestive heart failure &gt; class II NYHA, unstable angina pectoris,
             new onset of angina pectoris, myocardial infarction within the past 6 months, or
             cardiac ventricular arrhythmias requiring antiarrhythmic therapy

          -  The patient has experienced a hemorrhage or bleeding event â‰¥ NCI-CTCAE Grade 3 within
             4 weeks prior first dose of study therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85259</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Metairie</city>
        <state>Louisiana</state>
        <zip>70006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Burlington</city>
        <state>Massachusetts</state>
        <zip>01805</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 20, 2009</study_first_submitted>
  <study_first_submitted_qc>May 20, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 21, 2009</study_first_posted>
  <disposition_first_submitted>September 1, 2010</disposition_first_submitted>
  <disposition_first_submitted_qc>September 1, 2010</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">September 6, 2010</disposition_first_posted>
  <last_update_submitted>June 5, 2014</last_update_submitted>
  <last_update_submitted_qc>June 5, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 18, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatocellular Carcinoma</keyword>
  <keyword>Liver Neoplasms</keyword>
  <keyword>Antibodies, Monoclonal</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sorafenib</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>March 17, 2018</submitted>
    <returned>April 17, 2018</returned>
    <submitted>May 1, 2018</submitted>
  </pending_results>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

